Welcome to SpeeDx

 

SpeeDx Pty Ltd is a medical diagnostic company focused on the research, development and commercialisation of molecular diagnostic detection technologies and in vitro diagnostic tests.

SpeeDx’s vision is to positively impact humanity worldwide by developing molecular diagnostic detection technologies and products that enable faster, simpler, more accessible and cheaper diagnosis of disease.

SpeeDx’s proprietary technologies have differentiating features that drive penetration of tests into existing diagnostic markets and create new markets. These technologies include:

  • Multi-component nucleic acids (MNAzymes): enzymes composed of DNA that can be easily and cheaply adapted for sensitive,  specific multiplexed detection of many different target analytes;
  • DNAzymes: enzymes composed of DNA (through an exclusive license from The Scripps Research Institute – exclusive rights for human and animal health);
  • PASS: novel design feature for primers and/or MNAzyme components for highly sensitive multiplexed detection of gene mutations, allelic variations, and viral and bacterial strains;
  • EzyAmp: an isothermal signal amplification cascade utilising restriction enzymes; and
  • DNA-only-cascade (DOC): an isothermal signal amplification cascade utilising catalytic nucleic acid enzymes.

 

 


 

 

Copyright © SpeeDx Pty Ltd. All rights reserved.
ABN: 46 135 095 886 Terms and Conditions